Zacks: Analysts Expect UroGen Pharma Ltd. (NASDAQ:URGN) Will Post Quarterly Sales of $15.90 Million

Brokerages predict that UroGen Pharma Ltd. (NASDAQ:URGN) will post $15.90 million in sales for the current quarter, Zacks reports. Three analysts have made estimates for UroGen Pharma’s earnings. The lowest sales estimate is $15.70 million and the highest is $16.00 million. UroGen Pharma posted sales of $3.46 million during the same quarter last year, which suggests a positive year over year growth rate of 359.5%. The company is expected to announce its next earnings report on Monday, November 8th.

On average, analysts expect that UroGen Pharma will report full year sales of $55.57 million for the current year, with estimates ranging from $54.10 million to $57.10 million. For the next financial year, analysts forecast that the firm will report sales of $127.43 million, with estimates ranging from $114.50 million to $135.80 million. Zacks’ sales calculations are an average based on a survey of sell-side analysts that cover UroGen Pharma.

UroGen Pharma (NASDAQ:URGN) last released its quarterly earnings results on Wednesday, August 4th. The company reported ($1.17) earnings per share for the quarter, missing the consensus estimate of ($1.10) by ($0.07). The firm had revenue of $13.03 million for the quarter, compared to the consensus estimate of $13.00 million. UroGen Pharma had a negative net margin of 349.05% and a negative return on equity of 127.56%.

Separately, Zacks Investment Research lowered shares of UroGen Pharma from a “hold” rating to a “sell” rating in a research report on Tuesday, July 20th.

Hedge funds have recently bought and sold shares of the company. BNP Paribas Arbitrage SA increased its holdings in UroGen Pharma by 17.4% in the 1st quarter. BNP Paribas Arbitrage SA now owns 4,439 shares of the company’s stock worth $86,000 after acquiring an additional 657 shares in the last quarter. Public Employees Retirement System of Ohio boosted its holdings in UroGen Pharma by 21.1% in the 1st quarter. Public Employees Retirement System of Ohio now owns 6,900 shares of the company’s stock worth $134,000 after buying an additional 1,200 shares during the period. Algert Global LLC purchased a new stake in UroGen Pharma in the 1st quarter worth $227,000. State Board of Administration of Florida Retirement System purchased a new stake in shares of UroGen Pharma during the second quarter worth about $239,000. Finally, Wells Fargo & Company MN grew its position in shares of UroGen Pharma by 368.3% during the second quarter. Wells Fargo & Company MN now owns 19,916 shares of the company’s stock worth $304,000 after purchasing an additional 15,663 shares in the last quarter.

UroGen Pharma stock traded up $0.29 during mid-day trading on Friday, reaching $15.43. 549 shares of the stock traded hands, compared to its average volume of 160,216. The stock has a market capitalization of $322.49 million, a PE ratio of -3.01 and a beta of 1.22. The business’s 50-day moving average is $15.73 and its 200-day moving average is $17.39. UroGen Pharma has a 12-month low of $14.19 and a 12-month high of $28.20.

UroGen Pharma Company Profile

UroGen Pharma Ltd. is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases. It has developed RTGel reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs.

See Also: What is a growth and income fund?

Get a free copy of the Zacks research report on UroGen Pharma (URGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for UroGen Pharma (NASDAQ:URGN)

Receive News & Ratings for UroGen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UroGen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.